
Andrew Thomas Catanzaro MD
Washinton Advetist Infection Control, Antibiotic Stewardship Physician Leader
Join to view full profile
Phoenix Center at Unity Health Care1900 Mass Ave SEWashington, DC 20003
Phone+1 202-548-6500
Fax+1 202-355-7601
Dr. Catanzaro is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
MedStar Health Georgetown University/Georgetown HospitalFellowship, Infectious Disease, 1995 - 1996
MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 1992 - 1995
Virginia Commonwealth University School of MedicineClass of 1992
Certifications & Licensure
MD State Medical License 2013 - 2028
DC State Medical License 1997 - 2014
VA State Medical License 1993 - 2000
American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2016
- CMS Meaningful Use Stage 1 Certification Allscripts FollowMyHealth, Allscripts, 2016
- CMS Meaningful Use Stage 1 Certification Allscripts FollowMyHealth, Allscripts, 2016
Publications & Presentations
PubMed
- 1 citationsFostering an interdisciplinary culture of collaborative discussion to prevent central line-associated bloodstream infections.Ada J Baklouti, Andrew T Catanzaro, Norton Elson, Mabel Ankrah, James Rost
American Journal of Infection Control. 2026-06-01 - 26 citationsEfficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.James Welker, Juan D Pulido, Andrew T Catanzaro, Carlos D Malvestutto, Zihai Li
The Lancet. Infectious Diseases. 2022-05-01
Press Mentions
PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 PatientsJuly 16th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









